ASCO20: TERAVOLT provides insight into outcomes for cancer patients who develop COVID-19

Written by Rachel Jenkins, Future Science Group

The latest Thoracic cancERs international coVid 19 cOLlaboraTion (TERAVOLT) data recently presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that among thoracic cancer patients, prior use of chemotherapy was associated with increased mortality. “In less than a week we had a study enrolling patients,” commented lead author Leora Horn, MD, (Vanderbilt University Medical Center, TN, USA). “We have seen clinical trials being funded, approved and begin enrolling patients within weeks, when it can often take months or years to get approval for a trial.” Want regular updates straight to your inbox? Become a member of...

To view this content, please register now for access

It's completely free